

ATTACHMENT 1

***Curriculum Vitae* of Dr. Stephen Pakola**

Stephen J. Pakola, M.D.

11 Meadow Way
Irvington, NY 10533
Home Phone: 1-914-674-1947
email: steve.pakola@thrombogenics.com

Professional Summary: A licensed physician with over 13 years of clinical trial experience, including over 11 years of full-time Pharma/Biotech experience in roles of increasing responsibility (currently Chief Medical Officer of ThromboGenics and member of the Board of Directors of ThromboGenics Ltd.).

Education

M.D., University of Pennsylvania, Philadelphia, PA, 1994

- *Alpha Omega Alpha (national medical honor society) elected 1993
- *Charles A. Oliver Prize (awarded annually to a graduating medical student at the University of Pennsylvania), 1994

B.A., University of Pennsylvania, Philadelphia, PA, 1990

- *Summa cum laude (GPA-3.9) with honors in biology
- *Phi Beta Kappa, elected 1989

Professional Experience

- | | |
|--------------|---|
| 5/00-Present | Chief Medical Officer (Promoted from Senior VP in 6/06, promoted from VP on 7/02)
Member of the Board of Directors, ThromboGenics Ltd.
*Responsible for the company's worldwide clinical development programs (vitreoretinal disease, AMI, ischemic stroke, DVT prophylaxis, oncology, and other programs to enter clinical development in future)
*Program Leader for microplasmin-vitreoretinal program. |
| 11/98-5/00 | Associate Director, Cardiovascular Clinical Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

*U.S. clinical leader for oral direct thrombin inhibitor (BIBR) program
*Global Medical Leader of clinical development program for BIBB 1464, a lipid-lowering agent.
*Named to Clinical Expert Committee for risk factor intervention (internal expert group to review discovery/development plans for Boehringer Ingelheim worldwide) |
| 6/97-11/98 | Associate Director, Organon, Inc. CNS Clinical, West Orange, NJ |

- *Clinical Development Team Leader for gepirone (prior to departure, in charge of the preparation of the clinical section of NDA and clinical development plan for US)
- *Unit head award recipient, 1st quarter, 1998 (awarded by executive director of clinical department to employees who have made significant contributions to the department)
- *Study manager for 2 multicenter clinical trials (phase III ten-site trial and a phase IV, five-site trial)
- *Responsible for safety related issues for U.S. phase II-IV trials on all CNS projects.

1996-1997 Senior Medical Scientist, Cardiovascular Division, Quintiles, Inc., Research Triangle Park, N.C.

- *Project Medical Officer on all clinical trials in the U.S. Cardiovascular division, including phase I through global phase III trials (including GUARDIAN trial)
- *Presented at FDA Advisory Committee meeting, as well as numerous investigator meetings

1995-1996 Research Scientist and Ophthalmology Resident, University of Pennsylvania, F.M. Kirby Center for Gene Therapy

- *Planned and performed experiments in biotechnology arena, including virus vector gene transfer techniques
- *Authored multiple publications (including one book chapter), and presented work at 4 national meetings
- *Served as a reviewer for a medical journal

1994-1995 Medical Intern Physician, Presbyterian Medical Center (Affiliate of University of Pennsylvania Medical Center), Philadelphia, PA

Other

- *99% on GMAT (Graduate Management Admission Test)
- *Unrestricted license to practice medicine (License: NC 9700351)
- *Married with 3 children

Original Papers

Pakola SJ and Grunwald JE: Effects of oxygen and carbon dioxide on human retinal circulation. *Investigative Ophthalmology & Visual Science* 34(10): 2866-70, 1993.

MacGregor RR, Pakola SJ, Graziani AL, et al: CMV infection in clinically stable HIV-infected individuals with CD4-positive lymphocyte counts below 100/ul of blood: prevalence and relationship to risk of subsequent CMV retinitis. *Journal of AIDS* 10:324-30, 1995.

Pakola SJ, Dinges DF, Pack AI: Review of regulations and guidelines for commercial and non-commercial drivers with sleep apnea and narcolepsy. *Sleep* 18 (9): 787-96, 1995.

Pakola SJ, Nichols CW: CD8+ cells and cytomegalovirus retinitis in AIDS patients (correspondence). *Am. J. Ophthalmol.* 121(4): 455, 1996

Bennett J, Pakola S, Zenk Y, Maguire A: Humoral response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space. *Human Gene Therapy* 7(14): 1763-9, 1996

Balcer L, Galetta S, Bagley L, Pakola S: Localization of traumatic oculomotor nerve palsy to the midbrain exit sight by M.R.I. *Am. J. Ophthalmol.* 122(3): 437-9, 1996.

Lapchak PA, Araujo DM, Pakola SJ, Song D, Wei J, Zivin JA.: Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. *Stroke.* 33: 2279-2284, 2002.

Armstrong PW, Burton J, Pakola S, Molhoek PG, Betriu A, Tendera M, Bode C, Adgey AA, Bar F, Vahanian A, Van de Werf F; CAPTORS II Investigators. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). *Am Heart J.* 146(3):484-8, 2003.

Rasmussen RS, Overgaard K, Pakola S, Boysen G. Microplasmin may improve recovery in a rat embolic stroke model. *Neurol Res.* 2007 Jun 19; [Epub ahead of print].

Sakuma T, Tanaka M, Mizota A, Junji Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. *Invest Ophthalmol Vis Sci.* 2005 Sep;46(9):3295-9.

Chapters

Pack AI, Pakola SJ, Findley LJ: Regulations for driving for patients with sleep disorders. *Forensic aspects of sleep.* Edited by Shapiro C, McCall-Smith. A. John Wiley & Sons Limited, 1996.